Division of Nephrology, Shuwa General Hospital, 1200 Yahara-Shinden, Kasukabe, Saitama 344-0035, Japan.
Clin Exp Nephrol. 2011 Feb;15(1):121-5. doi: 10.1007/s10157-010-0360-6. Epub 2010 Nov 11.
Anemia is a common complication of patients with chronic kidney disease (CKD), which not only lowers their quality of life but also potentially causes cardiovascular diseases such as congestive heart failure and coronary heart disease, and accelerates the progression of renal dysfunction.
Pre-dialysis patients were assigned to groups A, B, C or D based on hemoglobin levels of ≤ 8.9 (n = 48), 9.0-9.9 (n = 63), 10-10.9 (n = 53), and ≥ 11.0 g/dL (n = 39), respectively. Cardiac function was estimated using echocardiography to clarify the relationship between anemia and cardiac disorders in patients with CKD immediately before starting hemodialysis.
Left ventricular ejection fraction (LVEF) was significantly higher in group D than in groups A and B. The fractions with an LVEF of less than 50% were 16.7, 4.8, 1.9, and 0% in groups A, B, C, and D, respectively. Posterior wall thickness was statistically thicker and the deceleration time of the early diastolic wave was longer in groups A and B, respectively, than in groups C and D. The left ventricular mass index in group D was significantly lower than in any other groups.
Anemia in pre-dialysis patients with CKD is a probable cause of impaired left ventricular systolic function and progressive left ventricular hypertrophy. Our results suggest that Hb levels should be maintained at >11 g/dL by EPO administration from the perspective of protecting cardiac function, although the upper limit of the target Hb level was undetermined.
贫血是慢性肾脏病(CKD)患者的常见并发症,不仅降低了他们的生活质量,还可能导致充血性心力衰竭和冠心病等心血管疾病,并加速肾功能障碍的进展。
根据血红蛋白水平将透析前患者分为 A、B、C 和 D 组,分别为≤8.9(n=48)、9.0-9.9(n=63)、10-10.9(n=53)和≥11.0 g/dL(n=39)。使用超声心动图评估心功能,以阐明 CKD 患者开始血液透析前贫血与心脏疾病之间的关系。
D 组的左心室射血分数(LVEF)明显高于 A 组和 B 组。LVEF 低于 50%的比例分别为 A、B、C 和 D 组的 16.7%、4.8%、1.9%和 0%。A 组和 B 组的后壁厚度分别大于 C 组和 D 组,且早期舒张波的减速时间较长。D 组的左心室质量指数明显低于其他组。
CKD 透析前患者的贫血可能是左心室收缩功能受损和进行性左心室肥厚的原因。我们的结果表明,尽管尚未确定目标 Hb 水平的上限,但从保护心脏功能的角度出发,应通过 EPO 给药将 Hb 水平维持在>11 g/dL。